biostudies-literaturePacheco YColciencias239https://www.ebi.ac.uk/biostudies/studies/S-EPMC5702157biostudies-literatureUnknown15(1)<h4>Background</h4>Evidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network. Thus, understanding how these complex nonlinear processes are connected and observed in real-life settings is a major challenge. Cluster approaches may assist in the identification of these subphenotypes, which represent such a phenomenon, and may contribute to the development of personalized medicine. Therefore, the relationship between autoantibody and cytokine clusters in SLE was analyzed.<h4>Methods</h4>This was an exploratory study in which 67 consecutive women with established SLE were assessed. Clinical characteristics including disease activity, a 14-autoantibody profile,Journal of translational medicineCytokine and autoantibody clusters interaction in systemic lupus erythematosus.PMC57021570425-2013122254531722Rojas MRamirez-Santana CAnaya JMRodriguez-Jimenez MMolano-Gonzalez NSaavedra JMantilla RDBarahona-Correa JAcosta-Ampudia YRodriguez YPacheco YMonsalve DMfalseCytokine and autoantibody clusters interaction in systemic lupus erythematosus.<h4>Background</h4>Evidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network. Thus, understanding how these complex nonlinear processes are connected and observed in real-life settings is a major challenge. Cluster approaches may assist in the identification of these subphenotypes, which represent such a phenomenon, and may contribute to the development of personalized medicine. Therefore, the relationship between autoantibody and cytokine clusters in SLE was analyzed.<h4>Methods</h4>This was an exploratory study in which 67 consecutive women with established SLE were assessed. Clinical characteristics including disease activity, a 14-autoantibody profile,2017-01-01T00:00:00Z2017 Nov2025-04-18T19:47:49.551Z2019-03-27T03:02:57ZS-EPMC57021572917889010.1186/s12967-017-1345-y